Heterogeneity in Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 24

PMID 35740696

Authors

Mei Fong Ng

Jacinta L Simmons

Glen M Boyle

Affiliations

Soon will be listed here.

Abstract

There is growing evidence that tumour heterogeneity has an imperative role in cancer development, evolution and resistance to therapy. Continuing advancements in biomedical research enable tumour heterogeneity to be observed and studied more critically. As one of the most heterogeneous human cancers, melanoma displays a high level of biological complexity during disease progression. However, much is still unknown regarding melanoma tumour heterogeneity, as well as the role it plays in disease progression and treatment response. This review aims to provide a concise summary of the importance of tumour heterogeneity in melanoma.

Citing Articles

Human CSPG4-targeting CAR-macrophages inhibit melanoma growth.

Greiner D, Xue Q, Waddell T, Kurudza E, Chaudhary P, Belote R Oncogene. 2025; .

PMID: 40082557 DOI: 10.1038/s41388-025-03332-0.

Ruthenium(II) Complex with 1-Hydroxy-9,10-Anthraquinone Inhibits Cell Cycle Progression at G0/G1 and Induces Apoptosis in Melanoma Cells.

Dias J, Ferreira-Silva G, Viana R, de Araujo Neto J, Ellena J, Correa R Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861126 PMC: 11768811. DOI: 10.3390/ph18010063.

Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.

Rafiepoor H, Ghorbankhanloo A, Soleimani Dorcheh S, Angouraj Taghavi E, Ghanadan A, Shirkoohi R J Cell Mol Med. 2025; 29(2):e70367.

PMID: 39823244 PMC: 11740884. DOI: 10.1111/jcmm.70367.

The role of mitophagy-related genes in prognosis and immunotherapy of cutaneous melanoma: a comprehensive analysis based on single-cell RNA sequencing and machine learning.

Tian J, Zhang L, Shi K, Yang L Immunol Res. 2025; 73(1):30.

PMID: 39799269 DOI: 10.1007/s12026-025-09593-x.

Morphological and Optical Profiling of Melanocytes and SK-MEL-28 Melanoma Cells Via Digital Holographic Microscopy and Quantitative Phase Imaging.

Farhat A, Almahdi Y, Alshuhani F, Xhabija B Adv Biol (Weinh). 2024; 9(2):e2400346.

PMID: 39526697 PMC: 11830431. DOI: 10.1002/adbi.202400346.

References

Maria Bosisio F, Antoranz A, Van Herck Y, Bolognesi M, Marcelis L, Chinello C . Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. Elife. 2020; 9. PMC: 7053517. DOI: 10.7554/eLife.53008. View

Busam K, Hedvat C, Pulitzer M, von Deimling A, Jungbluth A . Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2012; 37(3):413-20. DOI: 10.1097/PAS.0b013e318271249e. View

Simbulan-Rosenthal C, Dougherty R, Vakili S, Ferraro A, Kuo L, Alobaidi R . CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers (Basel). 2019; 11(10). PMC: 6827046. DOI: 10.3390/cancers11101490. View

Su Y, Ko M, Cheng H, Zhu R, Xue M, Wang J . Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nat Commun. 2020; 11(1):2345. PMC: 7214418. DOI: 10.1038/s41467-020-15956-9. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Caramel J, Papadogeorgakis E, Hill L, Browne G, Richard G, Wierinckx A . A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013; 24(4):466-80. DOI: 10.1016/j.ccr.2013.08.018. View

Janku F . Tumor heterogeneity in the clinic: is it a real problem?. Ther Adv Med Oncol. 2014; 6(2):43-51. PMC: 3932055. DOI: 10.1177/1758834013517414. View

Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C . Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007; 43(5):935-46. DOI: 10.1016/j.ejca.2007.01.017. View

Quintana E, Shackleton M, Sabel M, Fullen D, Johnson T, Morrison S . Efficient tumour formation by single human melanoma cells. Nature. 2008; 456(7222):593-8. PMC: 2597380. DOI: 10.1038/nature07567. View

10.

Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

11.

Munoz-Couselo E, Adelantado E, Ortiz C, Soberino Garcia J, Perez-Garcia J . -mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017; 10:3941-3947. PMC: 5558581. DOI: 10.2147/OTT.S117121. View

12.

Snyder D, Wang Y, Kaetzel D . A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 is highly metastatic in vivo. Sci Rep. 2020; 10(1):1971. PMC: 7005181. DOI: 10.1038/s41598-020-58996-3. View

13.

Manfredi L, Meyer N, Tournier E, Grand D, Uro-Coste E, Rochaix P . Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma. Acta Derm Venereol. 2015; 96(5):630-4. DOI: 10.2340/00015555-2326. View

14.

Lin Z, Meng X, Wen J, Corral J, Andreev D, Kachler K . Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients. Front Oncol. 2020; 10:596493. PMC: 7747763. DOI: 10.3389/fonc.2020.596493. View

15.

Wang Y, Leonard M, Snyder D, Fisher M, Eckert R, Kaetzel D . NME1 Drives Expansion of Melanoma Cells with Enhanced Tumor Growth and Metastatic Properties. Mol Cancer Res. 2019; 17(8):1665-1674. PMC: 6677611. DOI: 10.1158/1541-7786.MCR-18-0019. View

16.

Campagna R, Pozzi V, Sartini D, Salvolini E, Brisigotti V, Molinelli E . Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide -Methyltransferase as a Biomarker in Skin Cancers. Cancers (Basel). 2021; 13(19). PMC: 8508019. DOI: 10.3390/cancers13194943. View

17.

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann K, Speicher D . Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013; 23(6):811-25. PMC: 3810180. DOI: 10.1016/j.ccr.2013.05.003. View

18.

Smalley I, Kim E, Li J, Spence P, Wyatt C, Eroglu Z . Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine. 2019; 48:178-190. PMC: 6838387. DOI: 10.1016/j.ebiom.2019.09.023. View

19.

Travnickova J, Wojciechowska S, Khamseh A, Gautier P, Brown D, Lefevre T . Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease. Cancer Res. 2019; 79(22):5769-5784. PMC: 7116150. DOI: 10.1158/0008-5472.CAN-19-0037. View

20.

Simmons J, Pierce C, Al-Ejeh F, Boyle G . MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. Sci Rep. 2017; 7(1):10909. PMC: 5589904. DOI: 10.1038/s41598-017-11366-y. View